A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of PTG-100 in normal healthy volunteers

Trial Profile

A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of PTG-100 in normal healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs PTG 100 (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; First in man
  • Sponsors Protagonist Therapeutics
  • Most Recent Events

    • 14 Nov 2016 According to a Protagonist Therapeutics media release, data from this trial was be presented at United European Gastroenterology (UEG) Week 2016.
    • 19 Oct 2016 Results assessing safety presented at the 24th United European Gastroenterology Week
    • 13 Oct 2016 According to a Protagonist Therapeutics media release, data from this trial will be presented at United European Gastroenterology (UEG) Week 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top